日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression

剂量学分析表明，在PSMA高表达的非前列腺癌中，[¹⁷⁷Lu]Lu-PSMA-617清除迅速且吸收剂量低。

期刊:Ejnmmi Research
影响因子:3
doi:10.1186/s13550-026-01394-z
Khreish, Fadi; Rosar, Florian; Burgard, Caroline; Petto, Sven; Maus, Stephan; Stemler, Tobias; Bartholomä, Mark; Sabet, Amir; Schaefer-Schuler, Andrea; Ezziddin, Samer
肿瘤
前列腺癌
肿瘤免疫
发表日期：2026
文献求助 收藏

Auger Emitting [(161)Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal Carcinomatosis

俄歇发射[(161)Tb]Tb-PSMA-617放射性配体疗法治疗伴有腹膜癌的转移性去势抵抗性前列腺癌

期刊:Nuclear Medicine and Molecular Imaging
影响因子:2.7
doi:10.1007/s13139-025-00973-7
Rosar, Florian; Blickle, Arne; Bastian, Moritz B; Speicher, Tilman; Schaefer-Schuler, Andrea; Burgard, Caroline; Maus, Stephan; Ezziddin, Samer
肿瘤
前列腺癌
肿瘤免疫
发表日期：2026
文献求助 收藏

Pilot experience of [(161)Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry

在前瞻性注册研究中，对接受常规PSMA放射性激光治疗的转移性去势抵抗性前列腺癌（mCRPC）患者进行[(161)Tb]Tb-PSMA-617放射性激光治疗的试点研究结果显示，在接受常规PSMA放射性激光治疗后，转移性去势抵抗性前列腺癌（mCRPC）患者接受[(161)Tb]Tb-PSMA-617放射性激光治疗后，患者在接受[(161)Tb]Tb-PSMA-617放射性激光

期刊:Theranostics
影响因子:13.3
doi:10.7150/thno.115831
Rosar, Florian; Burgard, Caroline; Petrescu, Christine; Blickle, Arne; Bartholomä, Mark; Maus, Stephan; Bastian, Moritz B; Speicher, Tilman; Schaefer-Schuler, Andrea; Ezziddin, Samer
肿瘤
前列腺癌
肿瘤免疫
CRP
发表日期：2025
文献求助 收藏

Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3)

扩大 PSMA-RLT 的应用范围：评估对体能状态较差（ECOG 3）的难治性 mCRPC 患者的治疗效果

期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-025-07346-4
Bastian, Moritz B; Wörl, Benedikt; Blickle, Arne; Burgard, Caroline; Speicher, Tilman; Bartholomä, Mark; Schaefer-Schuler, Andrea; Maus, Stephan; Ezziddin, Samer; Rosar, Florian
CRP
发表日期：2025
文献求助 收藏

Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia

PSMA放射性配体疗法在伴有中度至重度血小板减少症的mCRPC患者中的安全性

期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-024-07006-z
Bastian, Moritz B; Sieben, Maike; Blickle, Arne; Burgard, Caroline; Speicher, Tilman; Bartholomä, Mark; Schaefer-Schuler, Andrea; Maus, Stephan; Ezziddin, Samer; Rosar, Florian
血小板
CRP
发表日期：2025
文献求助 收藏

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia

PSMA放射性配体疗法在基线轻度至中度白细胞减少的转移性前列腺癌患者中的耐受性

期刊:Ejnmmi Research
影响因子:3
doi:10.1186/s13550-025-01280-0
Bastian, Moritz B; Speicher, Tilman; Blickle, Arne; Burgard, Caroline; Bastian, Julius L D; Bartholomä, Mark; Schaefer-Schuler, Andrea; Maus, Stephan; Ezziddin, Samer; Rosar, Florian
细胞生物学
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

[(161)Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [(177)Lu]Lu-PSMA-617

[(161)Tb]Tb-PSMA-617 放射性配体疗法治疗转移性去势抵抗性前列腺癌 (mCRPC) 患者：初步剂量学结果及与 [(177)Lu]Lu-PSMA-617 的个体内直接比较

期刊:Theranostics
影响因子:13.3
doi:10.7150/thno.92273
Schaefer-Schuler, Andrea; Burgard, Caroline; Blickle, Arne; Maus, Stephan; Petrescu, Christine; Petto, Sven; Bartholomä, Mark; Stemler, Tobias; Ezziddin, Samer; Rosar, Florian
肿瘤
前列腺癌
肿瘤免疫
CRP
发表日期：2024
文献求助 收藏

Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival

PSMA-RLT 分子影像学和实验室基线生物标志物分析：全身总病灶 PSMA (TLP) 预测总生存期

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers16152670
Hein, Connor; Burgard, Caroline; Blickle, Arne; Bastian, Moritz B; Maus, Stephan; Schaefer-Schuler, Andrea; Hoffmann, Manuela A; Schreckenberger, Mathias; Ezziddin, Samer; Rosar, Florian
发表日期：2024
文献求助 收藏

Analysis of Molecular Imaging Biomarkers Derived from [(18)F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [(225)Ac]Ac-PSMA-617-Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy

对转移性去势抵抗性前列腺癌 (mCRPC) 患者 [(18)F]FDG PET/CT 衍生的分子影像生物标志物进行分析：全身总病灶糖酵解 (TLG) 可预测接受 [(225)Ac]Ac-PSMA-617 增强的 [(177)Lu]Lu-PSMA-617 放射性配体治疗患者的总生存期

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers16203532
Burgard, Caroline; Khreish, Fadi; Dahlmanns, Lukas; Blickle, Arne; Bastian, Moritz B; Speicher, Tilman; Maus, Stephan; Schaefer-Schuler, Andrea; Bartholomä, Mark; Petto, Sven; Ezziddin, Samer; Rosar, Florian
肿瘤
前列腺癌
肿瘤免疫
CRP
发表日期：2024
文献求助 收藏

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT

在PSMA-RLT治疗期间，采用FDG/PSMA双重PET显像预测mCRPC病灶进展。

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-024-61961-z
Rosar, Florian; Burgard, Caroline; David, Scott; Marlowe, Robert J; Bartholomä, Mark; Maus, Stephan; Petto, Sven; Khreish, Fadi; Schaefer-Schuler, Andrea; Ezziddin, Samer
CRP
发表日期：2024
文献求助 收藏